IRIS UniCatt

Pane, Marika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.163
EU - Europa 7.888
AS - Asia 7.821
SA - Sud America 1.693
AF - Africa 221
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 6
Totale 25.812
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.812
SG - Singapore 3.995
DE - Germania 2.104
CN - Cina 1.892
IT - Italia 1.571
BR - Brasile 1.402
SE - Svezia 886
NL - Olanda 827
FR - Francia 520
GB - Regno Unito 394
IE - Irlanda 386
VN - Vietnam 346
IN - India 275
ID - Indonesia 265
FI - Finlandia 222
RU - Federazione Russa 217
UA - Ucraina 216
HK - Hong Kong 201
CA - Canada 168
KR - Corea 137
PL - Polonia 128
AR - Argentina 120
JP - Giappone 116
MX - Messico 112
TR - Turchia 107
BD - Bangladesh 102
ES - Italia 80
IQ - Iraq 75
ZA - Sudafrica 69
AT - Austria 63
BE - Belgio 47
EC - Ecuador 46
PK - Pakistan 42
IR - Iran 38
LT - Lituania 35
CZ - Repubblica Ceca 34
CH - Svizzera 32
CO - Colombia 28
SA - Arabia Saudita 28
VE - Venezuela 28
AE - Emirati Arabi Uniti 26
CI - Costa d'Avorio 25
MA - Marocco 24
EG - Egitto 22
IL - Israele 21
KE - Kenya 21
PA - Panama 21
UZ - Uzbekistan 20
CL - Cile 19
JO - Giordania 19
PY - Paraguay 19
RO - Romania 17
RS - Serbia 15
TN - Tunisia 15
PH - Filippine 14
MK - Macedonia 13
BG - Bulgaria 12
PE - Perù 12
UY - Uruguay 12
AU - Australia 10
DO - Repubblica Dominicana 10
DZ - Algeria 10
KZ - Kazakistan 10
NP - Nepal 9
AZ - Azerbaigian 8
CR - Costa Rica 8
DK - Danimarca 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
OM - Oman 8
BY - Bielorussia 7
HU - Ungheria 7
SK - Slovacchia (Repubblica Slovacca) 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
AL - Albania 6
AM - Armenia 6
JM - Giamaica 6
MY - Malesia 6
NG - Nigeria 6
PT - Portogallo 6
SN - Senegal 6
BO - Bolivia 5
GE - Georgia 5
HR - Croazia 5
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
TH - Thailandia 5
GR - Grecia 4
HN - Honduras 4
NI - Nicaragua 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BH - Bahrain 3
EE - Estonia 3
ET - Etiopia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
NO - Norvegia 3
Totale 25.758
Salva come PNG Salva come JPEG
Città #
Singapore 2.214
Ashburn 1.031
Chandler 1.008
Amsterdam 706
San Jose 517
New York 417
Hefei 390
Dublin 351
Beijing 332
Los Angeles 308
Rome 291
Jakarta 246
Frankfurt am Main 239
Milan 232
Hong Kong 189
Munich 178
Dallas 161
San Mateo 150
São Paulo 148
Boston 134
Seoul 132
Ho Chi Minh City 124
Moscow 123
Jacksonville 122
Kent 110
Helsinki 109
Marseille 106
Chicago 101
Tokyo 101
Nanjing 99
Wilmington 95
Nürnberg 91
Houston 90
Warsaw 87
Buffalo 82
Hanoi 82
Princeton 78
Dearborn 77
Santa Clara 77
Ann Arbor 70
Nuremberg 67
The Dalles 66
Woodbridge 66
London 65
Montreal 65
Seattle 62
Atlanta 58
Brooklyn 57
Denver 57
Orem 55
Stockholm 53
Bremen 48
Chennai 48
Poplar 48
Johannesburg 47
Düsseldorf 44
Fairfield 44
Toronto 44
Mexico City 42
Nanchang 42
Phoenix 40
Brussels 39
Pune 37
San Francisco 37
Baghdad 36
Belo Horizonte 36
Boardman 36
Lappeenranta 35
Palermo 35
Paris 35
Rio de Janeiro 35
Lauterbourg 34
Redwood City 33
Shanghai 33
Turku 32
Ankara 31
Augusta 31
Lawrence 31
Brasília 30
Vienna 28
Hebei 27
Brno 26
Falkenstein 26
Lancaster 26
Abidjan 25
Cattolica 24
Detroit 24
Querétaro 24
Tianjin 24
Izmir 23
Bexley 22
Bologna 22
Dhaka 22
Manchester 22
City of London 21
Jiaxing 21
Kish 21
Mumbai 21
Norwalk 21
Turin 21
Totale 13.423
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 918
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 473
Validation and cross-cultural adaptation of the Italian version of the Pediatric Eating Assessment Tool (I-PEDI-EAT-10) in genetic syndromes 320
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 298
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 291
Cortical visual function in preterm infants in the first year. 265
Neurological examination of preterm infants a term equivalent age 259
Performance of Upper Limb module for Duchenne muscular dystrophy 220
Neurological examination at 6 to 9 months in infants with cystic periventricular leukomalacia 211
Prognostic value of EEG performed at term age in preterm infants. 210
Crossed cerebellar atrophy of prenatal onset 189
-Thalamic atrophy in infants with PVL and cerebral visual impairment 185
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 178
Developmental milestones in type I spinal muscular atrophy 171
A current approach to heart failure in Duchenne muscular dystrophy 169
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 169
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. 168
Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. 167
Visual development in prenatal post-haemorragic ventricular dilatation 163
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 160
Assessing floppy infants: a new module 157
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 157
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care? 155
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis 154
Muscle MRI in Becker muscular dystrophy 152
Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype-Genotype Correlation 150
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 145
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 143
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 141
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 141
Muscle MRI: Out of the tunnel. 140
A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy 140
Muscle MRI in Becker muscular dystrophy 139
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 139
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 138
Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol 138
Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era 138
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 138
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 136
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine 136
Salbutamol increases serviva motor neuron (SMN) patients: relevance for clinical trial design 136
Revised upper limb module for spinal muscular atrophy: Development of a new module 136
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 136
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy 135
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 134
Predominant distal muscle involvement in spinal muscular atrophy 134
Co-occurrence of fragile x syndrome with a second genetic condition: Three independent cases of double diagnosis 133
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study 132
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. 132
Respiratory function and therapeutic expectations in DMD: Families experience and perspective 132
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy 132
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study 131
Longitudinal assessments in discordant twins with SMA 128
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 126
Congenital muscular dystrophies with cognitive impairment. A population study 126
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 126
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 126
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 125
Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study 124
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 123
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 123
24 month longitudinal data in ambulant boys with duchenne muscular dystrophy 123
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 122
-Electroclinical patterns and evolution of epilepsy in the 4p- syndrome 122
MRI: Out of the tunnel. 122
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 122
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 121
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 120
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 120
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 120
6 minute walk test in duchenne MD patients with different mutations:12 month changes 119
Early Gross Motor Milestones in Duchenne Muscular Dystrophy 119
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 119
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 119
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 117
Longitudinal motor functional outcomes and magnetic resonance imaging patterns of muscle involvement in upper limbs in duchenne muscular dystrophy 117
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 116
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 116
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 116
Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis 115
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 114
Nusinersen in type 0 spinal muscular atrophy: should we treat? 114
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 113
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey 112
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 112
An observational study of functional abilities in infants, children, and adults with type 1 SMA. 111
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 111
Emergencies cards for neuromuscular disorders 1st Consensus Meeting from UILDM - Italian Muscular Dystrophy Association Workshop report 110
Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies. 110
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 110
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 109
Functional levels and MRI patterns of muscle involvement in upper limbs in Duchenne muscular dystrophy. 109
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 109
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 109
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 108
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study 108
Early treatment of type II SMA slows rate of progression of scoliosis 107
A Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable? 107
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 107
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 107
Totale 15.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021272 0 0 0 0 0 0 73 12 62 30 90 5
2021/20221.137 80 37 21 110 80 38 23 192 68 67 208 213
2022/20233.141 302 385 205 465 198 400 221 281 398 60 147 79
2023/20242.651 114 471 102 179 106 410 354 102 52 131 270 360
2024/20255.462 124 100 405 245 458 262 230 242 782 421 1.221 972
2025/202610.884 1.773 538 1.054 1.899 2.791 1.855 974 0 0 0 0 0
Totale 26.092